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Docking studiesAbstract In this study we examined the suitability of the 3H-imidazo[4,5-b]pyridine ring system in
developing novel anticancer and anti-inﬂammatory agents incorporating a diaryl pharmacophore. Eight
2,3-diaryl-3H-imidazo[4,5-b]pyridine derivatives retrieved from our in-house database were evaluated for
their cytotoxic activity against nine cancer cell lines. The results indicated that the compounds showed
moderate cytotoxic activity against MCF-7, MDA-MB-468, K562 and SaOS2 cells, with K562 being the
most sensitive among the four cancer cell lines. The eight 2,3-diaryl-3H-imidazo[4,5-b]pyridine
derivatives were also evaluated for their COX-1 and COX-2 inhibitory activity in vitro. The results
showed that compound 3f exhibited 2-fold selectivity with IC50 values of 9.2 and 21.8 mmol/L against
COX-2 and COX-1, respectively. Molecular docking studies on the most active compound 3f revealed a
binding mode similar to that of celecoxib in the active site of the COX-2 enzyme.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heterocycles with a vicinal diaryl substitution are an important
pharmacophore in medicinal chemistry and are key building
blocks for a variety of compounds showing anticancer and anti-
inﬂammatory activities1,2. The cytotoxic properties of these
compounds are mainly attributed to tubulin inhibition whereas
their anti-inﬂammatory activity is predominantly elicited through
the inhibition of cyclooxygenase (COX) enzymes (Fig. 1A)1,3.
Both activities require the diaryl pharmacophore with a cis-oleﬁn
conﬁguration4. Hence, several aromatic heterocyclic rings includ-
ing ﬁve-membered (pyrazole5, Imidazole6, thiazole5, furazan
(1,2,5-oxadiazole)7, oxazole6, isoxazole8, 1,2,3-thiadiazole9, tria-
zole10), six-membered (pyridine) and fused bicyclic rings, like
pyrazolo[1,5-a]pyrimidines11, quinazolinone, benzimidazole,
indole12, benzothiophene7 and benzofuran7, have been investi-
gated as a heterocyclic core in stabilizing the cis-oleﬁn orientation
of the two aryl rings (Fig. 1A). 3H-imidazo[4,5-b]pyridine
represents an interesting class of heterocyclic core for the design
of diaryl derivatives with anticancer and anti-inﬂammatory activ-
ities. Motivated by the above observations, the present research
strives to examine the utility of 3H-imidazo[4,5-b]pyridine as a
heterocyclic bridge for the design of novel 2,3-diaryl-3H-imidazo
[4,5-b]pyridine derivatives with anticancer and anti-inﬂammatory
activities. Eight compounds with either OH, OCH3 or both, or CF3
in aryl ring A and halo (F and Cl) or OCH3 substitution in aryl ring
B, were retrieved from our in-house database (Fig. 1B) and tested
for anticancer activity against a panel of nine cancer cell lines
(breast, prostate, colon, blood and bone cancer) and two non-
cancerous cell lines. The eight compounds were also evaluated for
their inhibitory on COX-1 and COX-2 enzymes. To the best our
knowledge, the cytotoxic and anti-inﬂammatory potential of this
class of compounds have not been reported in literature.2. Results and discussion
2.1. Chemistry
Diaryl substituted 3H-imidazo[4,5-b]pyridine derivatives were pre-
viously synthesized in our laboratory using a one pot synthetic
protocol from the corresponding N-aryl nitropyridines as shown inScheme 112. The requisite 3-nitro-N-aryl pyridin-2-amines (2a–c)
were prepared in situ by heating a mixture of 2-chloro-3-nitropyridine
(1a) and substituted anilines in DMSO at 100 oC. Subsequent
treatment of the DMSO solution of the resulting 3-nitro-N-phenyl-
pyridin-2-amine with aromatic aldehydes and sodium dithionite at
80 1C afforded the titled compounds in moderate to good yields. The
structures assigned to the compounds were supported by the data
obtained from IR, 1H NMR and mass spectral studies.
2.2. Cytotoxicity studies
The cytotoxic activity of eight diaryl substituted 3H-imidazo[4,5-
b]pyridine derivatives was evaluated against nine cancer cell lines
and two non-cancerous cell lines using the MTT assay. For many
of the cell lines, the concentration of the compounds had to be
over 100 μmol/L for any cell death to occur. For the prostate
cancer cell line DU-145, lung cancer cell line A549, and breast
cancer cell line MDAMB-231, none of the eight compounds
showed any effect as in Table 1. Minimal cell death was seen in
the pancreatic cancer cell line PANC-1, with compounds 3g and
3h having an IC50 of 83.54 and 57.69 μmol/L, respectively. Only
compound 3h had an effect on the colon cancer cell line HCT-15
with an IC50 of 66.92 μmol/L. The cancer cell lines that had the
most cell growth inhibition were MCF-7, MDA-MB-468, K562
and SaOS2. The compounds showed maximal growth inhibitory
potency against K562 with IC50 values ranging from 42 to 57
μmol/L. In the case of MCF-7 and SaOS2, growth inhibition was
observed at concentration ranging from 44 to 72 μmol/L and 52.5
to 71.5 μmol/L, respectively. Three compounds 3b, 3e and 3g
showed modest inhibition of MDA-MB-468 cell growth with IC50
values of 66.46, 78.82 and 69.34 μmol/L, respectively. The mouse
ﬁbroblast cell line KB-31 also had effects with IC50 values of 3b
of 74.96 μmol/L, 3e of 95.58 μmol/L, 3g of 64.36 μmol/L and 3h
of 70.91 μmol/L. The normal cell line used was HEK 293 and only
one of the compounds in the series, 3h, caused cell death with an
IC50 of 80 μmol/L.
2.3. COX inhibition studies
In addition to cytotoxic activity, the eight compounds were also
evaluated for COX-1 and COX-2 inhibitory activity as diaryl
pharmacophore is also an integral component of several COX
Scheme 1 Synthesis of 2,3-diaryl-3H-imidazo[4,5-b]pyridine derivatives (3a–3h).
Figure 1 (A) Structures of some biologically active molecules with diaryl pharmacophore and different heterocyclic scaffolds employed for
stabilizing the ‘cis’ diaryl conﬁguration in literature; (B) Structures of molecules 2,3-diaryl-3H-imidazo[4,5-b]pyridine derivatives evaluated in
this study.
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clearly demonstrate the effectiveness of all 3H-imidazo[4,5-b]pyridine
derivatives against both COX-1 and COX-2 enzymes. The com-
pounds inhibited COX-1 with IC50 values ranging from 10 to
43 μmol/L, whereas COX-2 inhibition was observed in concentration
ranging from 9.2 to 279.3 μmol/L. Most notably, structural variations
in both aryl rings appeared to affect both the potency and selectivity
of these analogues against these enzymes. This is a desirable trait
especially for the development of clinically useful anti-inﬂammatory
agents targeting the COX-2 enzyme. Compound 3f with a 4-chloro
substitution in the N-phenyl ring and a 3-CF3 substitution in the 2-
phenyl ring was found to be the most active (COX-2, IC50 ¼
9.2 μmol/L) in the series. Compounds 3c that had 4-ﬂuoro and 3-CF3
substitutions on the N-phenyl and 2-phenyl rings, respectively and
compound 3h that possessed 3,4-dimethoxyl and 3-OCH3, 4-OH
substituents in the same positions exhibited the modest COX-2
inhibitory activity (IC50 E 15 μmol/L).2.4. Docking studies
Molecular docking studies were proposed for compound 3f in
order to rationalize its potency and selectivity against COX-2.Prior to docking studies with compound 3f, the glide docking
protocol was validated by evaluating the ability to reproduce the
binding conformation of the co-crystallized ligand celecoxib. The
docking protocol followed was found reliable as the root mean
square deviation (RMSD) between the predicted conformation and
the observed X-ray crystallographic conformation of the celecoxib
(PDB ID: 3LN1) was found to be 0.33 Å. The binding mode
predicted for 3f in the docking studies is shown in Fig. 2A. The
binding mode observed for 3f is very similar to the one observed
for the co-crystallized celecoxib (Fig. 2B). The docked structures
of 3f and celecoxib were oriented so that the N-phenyl ring of 3f
overlapped with that of 4-sulfamoylphenyl ring in celecoxib in the
selectivity pocket of COX-2 and the 3H-imidazo[4,5-b]pyridine
ring overlapped with the triﬂuoromethyl substituted pyrazolyl ring
in celecoxib. Furthermore, the chlorine atom at the p-position of
the N-phenyl ring is favorably placed in the selectivity pocket
facilitating electrostatic interactions with Arg499 and Phe504.
However, the 2-phenyl ring in 3f is more planar in comparison to
the second phenyl ring in celecoxib, resulting in a partial overlap
of both these rings. This deviation in the orientation of the 2-
phenyl ring might serve to accommodate the 3-triﬂuoromethyl
substitution in the hydrophobic pocket formed by Phe367, Leu370,
Trp373 and Met508. Nevertheless, the binding parallels observed
Table 2 COX inhibition data of 2,3-diaryl-3H-imidazo[4,5-
b]pyridine derivatives.
Compd. IC50 (mmol/L) Selectivity ratio
COX-1 COX-2 COX-2/COX-1
3a 10.070.01 35.972.0 3.59
3b 15.070.13 NA NA
3c 36.071.4 15.170.9 0.42
3d 42.772.5 25.671.0 0.60
3e 16.870.1 279.377.2 16.58
3f 21.871.1 9.270.02 0.42
3g 19.170.3 22.472.5 1.17
3h 18.570.00 15.473.1 0.83
Indomethacin 0.006770.00 0.04870.00 7.16
Celecoxib 1570.6 0.04270.00 0.0028
NA: not achieved at the tested concentrations.
Table 1 Cytotoxic activity of 2,3-diaryl-3H-imidazo[4,5-b]pyridine derivatives against various cell lines (cancerous and non-cancerous).
Compd. IC50 (mmol/L)
Breast Prostate Pancreas
MCF-7 MDAMB-231 MDAMB-468 DU-145 PANC-1
3a 61.5 4100 4100 4100 4100
3b 69 4100 66.46 4100 4100
3c 44 4100 4100 4100 4100
3d 72 4100 4100 4100 4100
3e 60 4100 78.82 4100 4100
3f 49.9 4100 4100 4100 4100
3g 56 4100 69.34 4100 83.54
3h 53 4100 4100 4100 57.69
Compd. IC50 (mmol/L )
Blood Bone Colon Lung Normal Mouse ﬁbroblast
K562 SaoS2 HCT15 A549 HEK293 KB-31
3a 49 64 4100 4100 4100 4100
3b 46 67 4100 4100 4100 74.96
3c 42 52.5 4100 4100 4100 4100
3d 57 71.5 4100 4100 4100 4100
3e 53 62.5 4100 4100 4100 95.58
3f 43 53.5 4100 4100 4100 4100
3g 47 55 4100 4100 4100 64.36
3h 54.5 59 66.92 4100 80 70.91
Erin Marie Kirwen et al.76between celecoxib and 3f may rationalize the inhibitory potency
shown by the compound against COX-2 enzyme.3. Conclusions
The present study is an attempt to examine the suitability of 3H-
imidazo[4,5-b]pyridine as a heterocyclic core for the development
of anticancer and anti-inﬂammatory molecules incorporating a
diaryl pharmacophore. Eight 1,2-diaryl-3H-imidazo[4,5-b]pyridines
retrieved from our in-house database were evaluated for their
cytotoxic activity against nine cancer cell lines and COX (1 and
2) inhibitory activity in vitro. The compounds showed moderate
cytotoxicity against MCF-7, MDA-MB-468, K562, and SaOS2 cells
with K562 being the most sensitive among the four cancer cell lines.The compounds also exerted inhibitory activity against both the
COX-1 and COX-2 enzymes. Most interesting was compounds 3c,
3f and 3h, which showed potent (IC50 o 20 μmol/L) and selective
COX-2 inhibition. The docking study of the most active analogue 3f
into the COX-2 active site supported the in vitro potency shown by
the compound and also revealed the nature of the interactions
between the molecule and amino acid residues in the active site of
COX-2. Taken together, these promising ﬁndings established 1,2-
diaryl-3H-imidazo[4,5-b]pyridines as a promising scaffold in devel-
oping anticancer and anti-inﬂammatory agents.4. Experimental
4.1. Chemistry
All chemicals and solvents used in this study were purchased
locally from commercial suppliers and were used without further
puriﬁcation. Melting points were determined on a Veego Digital
Melting Point apparatus in open capillaries and have not been
corrected. The 1H NMR spectra were recorded on in DMSO-d6 on
a Bruker Avance II 400 MHz spectrometer. Chemical shifts were
recorded in parts per million (ppm) and were reported relative to
tetramethylsilane (TMS). The infrared (IR) spectra were recorded
on a Schimadzu IR Prestige-21 FTIR spectrophotometer in KBr.
Mass spectra were recorded on an Applied Biosystem QTRAP
3200 MS/MS system in ESI mode.
4.1.1. Synthesis of 2,3-diaryl-3H-imidazo[4,5-b]pyridine
derivatives (3a–3h)
The synthesis of 2,3-diaryl-3H-imidazo[4,5-b]pyridine derivatives
(3a–3h) was performed according to a reported literature
procedure13.
Figure 2 (A) XP-Glide predicted binding mode of 3f in the active site of COX-2 (PDB ID: 3LN1); (B) Overlay of docked conformation of 3f on
docked conformation of celecoxib (yellow) in the active site of COX-2. Important amino acids are depicted as sticks with the atoms colored as
carbon (green), hydrogen (white), nitrogen (blue), oxygen (red), sulfur (yellow), whereas the ligands are shown with the same color scheme as
above except for carbon atoms are represented in yellow for 3f and orange for celecoxib. Fluorine atoms in 3f are represented in light green and
chlorine atom is represented in dark green. Red dotted lines represent hydrogen bonding.
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Yield 44%; m.p. 235–236 oC; FT-IR (KBr) υ (cm1): 3184
(O-H), 3059 (aromatic C-H), 1589 (C¼N), 1388 (C-N), 1224 (C-
F), 1159 (C-O); 1H NMR (400 MHz, DMSO-d6) δ 9.35 (s, 1H,
ArOH), 8.26 (d, 1H, J¼4.72 Hz, ArH), 8.05 (d, 1H, J¼8.0 Hz,
ArH), 7.38–7.35 (m, 2H, ArH), 7.29–7.26 (m, 1H, ArH), 7.18
(t, 2H, J¼8.52 Hz, ArH), 7.08 (t, 1H, J¼7.92 Hz, ArH), 7.03
(s, 1H, ArH), 6.88 (d, 1H, J¼7.72 Hz, ArH), 6.84 (d, 1H, J¼4.12
Hz, ArH); MS-API: [MþH]þ 306 (Calcd. 305.10).
3-(4-Fluorophenyl)-2-(3-methoxyphenyl)-3H-imidazo[4,5-b]pyri-
dine (3b): Yield 57%; m.p. 236–237 oC; FT-IR (KBr) υ (cm1): 3053
(C-H aromatic), 2955 (methyl C-H), 1593 (C¼N), 1381 (C-N),
1230 (C-F), 1251, 1033 (C-O-C); 1H NMR (400 MHz,
DMSO-d6): δ 8.39 (d, 1H, J¼4.8 Hz, ArH), 8.16 (d, 1H,
J¼8.04 Hz, ArH), 7.39–7.36 (m, 2H, ArH), 7.33–7.30 (m, 1H, ArH),
7.26–7.18 (m, 4H, ArH), 7.125–7.09 (m, 1H, ArH), 6.97–6.95 (m, 1H,
ArH), 3.74 (s, 3H, -OCH3); MS-API: [MþH]þ 320 (Calcd. 319.11).
3-(4-Fluorophenyl)-2-(3-(triﬂuoromethyl)phenyl)-3H-imidazo
[4,5-b]pyridine (3c): Yield 26%; m.p. 185–187 oC; FT-IR (KBr) υ
(cm1): 3068 (aromatic C-H), 1599 (C¼N), 1383 (C-N), 1228
(C-F,CF3), 1185 (C-F);
1H NMR (400 MHz, DMSO-d6): δ 8.43 (d,
1H, J¼4.76 Hz, ArH), 8.19 (d, 1H, J¼9.2 Hz, ArH), 7.96 (s, 1H,
ArH), 7.72–7.66 (m, 2H, ArH), 7.47 (t, 1H, J¼7.92 Hz, ArH),
7.39–7.34 (m, 3H, ArH), 7.27–7.22 (m, 1H, ArH); MS-API:
[MþH]þ 358 (Calcd. 357.1).
4-(3-(4-Fluorophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)-2-meth-
oxyphenol (3d): Yield 44%; m.p. 244–246 oC; FT-IR (KBr) υ
(cm1): 3063 (O-H), 2972 (C-H),1585 (C¼N), 1386 (C-N), 1228
(C-F), 1249, 1024 (C-O-C); 1H NMR (400 MHz, DMSO-d6): δ
9.047 (s, 1H, ArOH), 8.233 (d, 1H, J¼9.44 Hz, ArH), 8.0 (d, 1H,
J¼7.9 Hz, ArH), 7.36–7.33 (m, 2H, ArH), 7.24–7.16 (m, 3H,
ArH), 7.09 (s, 1H, ArH), 6.9 (d, 1H, J¼8.28 Hz, ArH), 6.73 (d, 1H,
J¼8.24 Hz, ArH), 3.66 (s, 3H, OCH3); MS-API: [MþH]þ 336
(Calcd. 335.11).
5-(3-(4-Fluorophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)-2-meth-
oxyphenol (3e): Yield 85%; m.p. 190–192 oC; FT-IR (KBr) υ
(cm1): 3117 (O-H), 2964 (methyl C-H), 1606 (C¼N), 1363(C-N), 1228 (C-F), 1253, 1026 (C-O-C); 1H NMR (400 MHz,
DMSO-d6): δ 8.97 (s, 1H, ArOH), 8.28 (d, 1H, J¼4.8 Hz, ArH),
8.06 (d, 1H, J¼7.96 Hz, ArH), 7.43–7.40 (m, 2H, ArH),
7.31–7.24 (m, 3H, ArH), 7.16 (s, 1H, ArH), 7.091 (s, 1H, ArH),
6.95 (d, 1H, J¼8.16 Hz, ArH), 6.82 (d, 1H, J¼8.48 Hz, ArH),
3.86 (s, 3H, OCH3); MS-API: [MþH]þ 336 (Calcd. 335.11).
3-(4-Chlorophenyl)-2-(3-(triﬂuoromethyl)phenyl)-3H-imidazo
[4,5-b]pyridine (3f): Yield 68%; m.p. 220–223 oC; FT-IR (KBr) υ
(cm1): 3045 (aromatic C-H), 1591 (C¼N), 1383 (C-N), 1329
(C-F, CF3), 1095 (C-Cl);
1H NMR (400 MHz, DMSO-d6): δ 8.43
(d, 1H, J¼4.8 Hz, ArH), 8.18 (d, 1H, J¼8.0 Hz, ArH), 8.02
(s, 1H, ArH), 7.67 (t, 2H, J¼8.12 Hz, ArH), 7.54–7.45 (m, 3H, ArH),
7.37–7.32 (m, 3H, ArH); MS-API: [MþH]þ 374 (Calcd. 373.06).
3-(4-Chlorophenyl)-2-(3,4,5-trimethoxyphenyl)-3H-imidazo[4,5-b]
pyridine (3g): Yield 88%; m.p. 193–195 oC; FT-IR (KBr) υ (cm1):
3024 (aromatic C-H), 2962 (methyl C-H), 1587 (C¼N), 1373
(C-N), 1240, 1010 (C-O-C), 1089 (C-Cl); 1H NMR (400 MHz,
DMSO-d6): δ 8.31 (d, 1H, J¼4.88 Hz, ArH), 8.07 (d, 1H, J¼8.0
Hz, ArH), 7.47–7.44 (m, 2H, ArH), 7.32–7.29 (m, 2H, ArH),
7.26–7.23 (m, 1H, ArH), 6.75 (s, 2H, ArH), 3.81 (s, 3H, OCH3),
3.63 (s, 6H, OCH3); MS-API: [MþH]þ 396 (Calcd. 395.1).
5-(3-(3,4-Dimethoxyphenyl)-3H-imidazo[4,5-b]pyridin-2-yl)-2-
methoxyphenol (3h): Yield 52%; m.p. 193–195 oC; FT-IR (KBr)
υ (cm1): 3200 (O-H), 3066 (C-H aromatic), 2945 (methyl C-H),
1597 (C¼N), 1384 (C-N), 1240, 1018 (C-O-C); 1H NMR (400
MHz, DMSO-d6): δ 8.35 (d, 1H, J¼4.84Hz, ArH), 8.11 (d, 1H,
J¼8.0 Hz, ArH), 7.29–7.26 (m, 3H, ArH), 6.99 (s, 2H, ArH), 6.84
(s, 1H, ArH), 6.79 (d, 1H, J ¼ 8.52 Hz, ArH) 3.95 (s, 3H, OCH3),
3.88 (s, 3H, OCH3), 3.8 (s, 3H, OCH3); MS-API: [MþH]þ 378
(Calcd. 377.14).4.2. Pharmacology
4.2.1. Cytotoxicity studies
Lung cancer cell line A549, colon carcinoma cell line HCT-15,
breast carcinoma cell lines MDA-MB-231 and MDA-MB-468,
Erin Marie Kirwen et al.78prostatic cancer cell line DU-145, pancreatic cancer cell line
PANC-1, human embryonic kidney cells HEK293, and mouse
ﬁbroblast KB-31 were grown as adherent monolayers in ﬂasks
with Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) in a humidiﬁed incubator
containing 5% CO2 at 37
oC. The human cancerous cell lines
MCF-7 (breast cancer), SaOS-2 (osteosarcoma), and K562 (mye-
logenous leukemia) were maintained in Eagle's minimal essential
medium, McCoy's 5a medium and RPMI-1640, respectively, and
supplemented with NaHCO3, sodium pyruvate, 10% fetal calf
serum, and 1% penicillin and streptomycin. These cells were
grown at 37 oC, 5% CO2 in a humidiﬁed air.
The MTT assay was used to determine the cytotoxicity of the
compounds to the following cells: HCT-15, MCF-7, MDA-MB-
231, MDA-MB-468, SaOS-2, K562, DU-145, PANC-1, HEK293,
and KB-31. Brieﬂy, the cells used in this study were harvested
with trypsin and suspended at a ﬁnal concentration of 5 103 cells
in each well. Cells were seeded (180 mL/well) into 96-well
multiplates. Different concentrations of each compound in the
series (20 mL) were added. After 72 h of incubation, 20 mL of the
MTT solution (4 mg/mL) was added to each well, and the plates
were incubated for 4 h. This allowed viable cells to convert the
yellow-colored MTT into dark-blue formazan crystals. Subse-
quently, the medium was discarded, and 100 mL of DMSO was
added into each well to dissolve the formazan crystals. The
absorbance was determined at 570 nm with a DTX 880 multimode
detector. The mean 7 SD concentrations were calculated from
2 to 3 experiments performed in triplicate. The IC50 values were
calculated from the cell survival percentages.
4.2.2. Assays for COX-1 and COX-2 inhibition
COX-1 has been isolated from Ram seminal vesicles. Recombi-
nant human COX-2 has been expressed in an insect cell expression
system. These enzymes have been puriﬁed by employing conven-
tional chromatographic techniques. Enzymatic activities of COX-1
and COX-2 were measured according to the method13 with slight
modiﬁcations using a chromogenic assay based on the oxidation of
N,N,N',N',-tetramethyl-p-phenylene diamine (TMPD) during the
reduction of PGG2 to PGH214,15. Brieﬂy, the assay mixture
containing Tris HCl buffer (100 mmol/L, pH 8.0), hematin
(15 mmol/L), EDTA (3 mmol/L), enzyme (100 mg COX-1 or
COX-2) and the test compound were pre-incubated at 25 1C for
1 min and then the reaction was initiated by the addition of
arachidonic acid and TMPD, in total volume of 1 mL. The enzyme
activity was determined by estimating the velocity of TMPD
oxidation for the ﬁrst 25 s of the reaction by following the increase
in absorbance at 603 nm. A low rate of non-enzymatic oxidation
observed in the absence of COX-1 and COX-2 was subtracted
from the experimental value while calculating the percent
inhibition.
4.3. Molecular docking studies
The docking analysis of most active molecule was performed
using Maestro (version 9.2; Schrödinger, LLC: New York, NY,
USA, 2012). The molecules were sketched in 3D format using
build panel and LigPrep module was used to produce low-energy
conformers. The structural coordinates of COX-216 was obtained
from protein data bank. The protein was prepared by giving
preliminary treatment like adding hydrogen atoms, adding missing
residues, reﬁning the loop with prime and ﬁnally minimized usingthe OPLS-2005 force ﬁeld. Grid for molecular docking was
generated with bound co-crystallized ligand (celecoxib). The
molecules were docked using Glide (version 5.7; Schrödinger,
LLC: New York, NY, 2012) in the extra-precision mode, with up
to three poses saved. Ligands were kept ﬂexible by producing the
ring conformations and by penalizing non-polar amide bond
conformations, whereas the receptor was kept rigid throughout
the docking studies. All other parameters of the Glide module were
maintained at their default values. The lowest energy conformation
was selected for the prediction of ligand interactions with the
active sites of COX-2.
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